Literature DB >> 19927353

Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD.

Stefan Hacker1, Christopher Lambers, Andreas Pollreisz, Konrad Hoetzenecker, Michael Lichtenauer, Andreas Mangold, Tina Niederpold, Andreas Hacker, György Lang, Martin Dworschak, Thomas Vukovich, Christopher Gerner, Walter Klepetko, Hendrik Jan Ankersmit.   

Abstract

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a worldwide burden and a major cause of death. The disease is accompanied by chronic inflammation and increased cellular turnover that is partly due to an overwhelming induction of apoptosis. In this study, we hypothesized that systemic markers of apoptosis are altered in patients with mild-to-severe COPD.
MATERIALS AND METHODS: A total number of 64 patients and controls were enrolled in the study. Lung function parameters of all groups (nonsmoker, healthy smoker, COPD GOLD I&II, COPD GOLD III&IV) were evaluated at the time of inclusion. Enzyme-linked immunosorbent assays were used to quantify protein levels in serum samples.
RESULTS: Serum contents of apoptotic end-products caspase-cleaved cytokeratin-18 and histone-associated-DNA-fragments were increased in patients with COPD, whereas anti-inflammatory soluble ST2 showed a peak in patients with COPD I&II (P=0.031) compared to healthy smokers. Levels of pro-inflammatory caspase-1/ ICE correlated significantly with the number of pack years (R=0.337; P=0.007). DISCUSSION: Our results indicate a systemic release of apoptosis-specific proteins as markers for increased cellular turnover accompanied by progression of COPD. Furthermore, soluble ST2 seems to have a critical role in the anti-inflammatory regulatory mechanism at early stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19927353      PMCID: PMC6649135          DOI: 10.1002/jcla.20348

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  44 in total

Review 1.  The Toll-receptor family and control of innate immunity.

Authors:  E B Kopp; R Medzhitov
Journal:  Curr Opin Immunol       Date:  1999-02       Impact factor: 7.486

Review 2.  The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders.

Authors:  H E Barksby; S R Lea; P M Preshaw; J J Taylor
Journal:  Clin Exp Immunol       Date:  2007-06-21       Impact factor: 4.330

3.  Secretion of soluble ST2 - possible explanation for systemic immunosuppression after heart surgery.

Authors:  T Szerafin; T Niederpold; A Mangold; K Hoetzenecker; S Hacker; G Roth; M Lichtenauer; M Dworschak; E Wolner; H J Ankersmit
Journal:  Thorac Cardiovasc Surg       Date:  2009-01-23       Impact factor: 1.827

4.  A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes.

Authors:  N A Thornberry; H G Bull; J R Calaycay; K T Chapman; A D Howard; M J Kostura; D K Miller; S M Molineaux; J R Weidner; J Aunins
Journal:  Nature       Date:  1992-04-30       Impact factor: 49.962

Review 5.  COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity.

Authors:  David M Mannino
Journal:  Chest       Date:  2002-05       Impact factor: 9.410

6.  Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors.

Authors:  Robert Newton; Neil S Holden; Matthew C Catley; Wale Oyelusi; Richard Leigh; David Proud; Peter J Barnes
Journal:  J Pharmacol Exp Ther       Date:  2007-02-22       Impact factor: 4.030

Review 7.  ICE-like proteases in apoptosis.

Authors:  S Kumar
Journal:  Trends Biochem Sci       Date:  1995-05       Impact factor: 13.807

8.  Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation.

Authors:  Hiroko Hayakawa; Morisada Hayakawa; Akihiro Kume; Shin-ichi Tominaga
Journal:  J Biol Chem       Date:  2007-07-10       Impact factor: 5.157

9.  Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.

Authors:  Don D Sin; S F Paul Man
Journal:  Circulation       Date:  2003-03-25       Impact factor: 29.690

10.  An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema.

Authors:  Sandra Grumelli; David B Corry; Li-Zhen Song; Ling Song; Linda Green; Joseph Huh; Joan Hacken; Rafael Espada; Remzi Bag; Dorothy E Lewis; Farrah Kheradmand
Journal:  PLoS Med       Date:  2004-10-19       Impact factor: 11.069

View more
  16 in total

1.  A comparative study of apoptosis in placentas of normal and preeclamptic Indian pregnant women by TUNEL assay and M30 immunostaining.

Authors:  Mona Sharma; Rani Kumar; Neerja Bhatla; Renu Dhingra
Journal:  J Clin Lab Anal       Date:  2012-11       Impact factor: 2.352

2.  Elevations in Circulating sST2 Levels Are Associated With In-Hospital Mortality and Adverse Clinical Outcomes After Blunt Trauma.

Authors:  Isabel M Billiar; Jesse Guardado; Othman Abdul-Malak; Yoram Vodovotz; Timothy R Billiar; Rami A Namas
Journal:  J Surg Res       Date:  2019-07-03       Impact factor: 2.192

3.  Genetics of interleukin 1 receptor-like 1 in immune and inflammatory diseases.

Authors:  Loubna Akhabir; Andrew Sandford
Journal:  Curr Genomics       Date:  2010-12       Impact factor: 2.236

4.  High levels of lung resident CD4+CD28null cells in COPD: implications of autoimmunity.

Authors:  K Hoetzenecker; A Mitterbauer; E Guenova; T Schweiger; P Altmann; M Zimmermann; H Hofbauer; L Beer; W Klepetko; H J Ankersmit
Journal:  Wien Klin Wochenschr       Date:  2013-03-27       Impact factor: 1.704

5.  Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice.

Authors:  Chuan Qiu; Yan Li; Mingcai Li; Min Li; Xiaojin Liu; Charles McSharry; Damo Xu
Journal:  Immunology       Date:  2013-01       Impact factor: 7.397

6.  Soluble ST2, a modulator of the inflammatory response, in preterm and term labor.

Authors:  Tamara Stampalija; Tinnakorn Chaiworapongsa; Roberto Romero; Adi L Tarca; Gaurav Bhatti; Po Jen Chiang; Nandor Gabor Than; Enrico Ferrazzi; Sonia S Hassan; Lami Yeo
Journal:  J Matern Fetal Neonatal Med       Date:  2013-11-13

Review 7.  Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome.

Authors:  Laura Santambrogio; Hans-Georg Rammensee
Journal:  Immunogenetics       Date:  2018-10-20       Impact factor: 2.846

8.  The Role of SNPs in IL1RL1 and IL1RAP Genes in Age-related Macular Degeneration Development and Treatment Efficacy.

Authors:  Alvita Vilkeviciute; Neringa Bastikaityte; Ruta Mockute; Dzastina Cebatoriene; Loresa Kriauciuniene; Jurate Balciuniene; Reda Zemaitiene; Rasa Liutkeviciene
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

9.  IL1RL1 gene variants and nasopharyngeal IL1RL-a levels are associated with severe RSV bronchiolitis: a multicenter cohort study.

Authors:  Tina E Faber; Annemieke Schuurhof; Annelies Vonk; Gerard H Koppelman; Marije P Hennus; Jan L L Kimpen; Riny Janssen; Louis J Bont
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

Review 10.  Cytokine inhibition in the treatment of COPD.

Authors:  Gaetano Caramori; Ian M Adcock; Antonino Di Stefano; Kian Fan Chung
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.